Why Formulary Management Is Now an IP Discipline The pharmaceutical formulary started its modern life as an administrative cost control […]
The 80/80 Paradox: What the Numbers Actually Say The U.S. pharmaceutical market runs on a structural contradiction that no other
The United States pharmaceutical market operates within a network of opaque intermediaries that disconnect manufacturing costs from patient expenditures. Billionaire
Dunking on the Pharma Industry: An In-Depth Analysis of Mark Cuban’s War on Drug Prices Read Post »
1. Why Patent Defense Is a Corporate Strategy Problem, Not a Legal One Patent defense gets handed to legal teams.
1. Executive Summary The pharmaceutical industry’s API manufacturing layer is undergoing a structural break, not an upgrade cycle. The convergence
A deep-dive for pharma IP teams, portfolio managers, and institutional investors on the strategies, IP valuations, and commercial mechanics that
Drug Patent Challenges: Win the Market, Not Just the Lawsuit Read Post »
The biopharma industry has spent decades optimizing for efficiency. Lean supply chains, single-source API relationships, centralized cell storage, and just-in-time
Biomedical Business Continuity: Build Resilience or Lose Market Share Read Post »
Own the Market After Your Patent Dies A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and
How to own a Market you Don’t Own: Market Access Strategies Post-Drug Patent Expiration Read Post »
Why Formulation Patents Are the Most Undervalued Asset in Pharma IP The pharmaceutical industry spent roughly $260 billion on R&D
Sign in or create a free account to read this DrugPatentWatch article
